Oncocyte

Oncocyte Completes Validation of TheraSure™ Transplant Monitor Test

Retrieved on: 
Thursday, May 5, 2022
COVID-19, Forward-looking statement, Nasdaq, Maintenance, Failure, GLOBE, Accounting, Company, CTO, Kidney, Physician, Tumor microenvironment, PCR, Patient, Doctor of Philosophy, Certification, West Pharmaceutical Services explosion, Technology transfer, End organ damage, Neoplasm, Cancer, Diagnosis, Polymerase, DNA, Workflow, Heart transplantation, Disease, CLIA, Liver, Intellectual property, U.S. Securities and Exchange Commission, SEC, Goal, CEO, Technology, OCX, Recurrence, Acquisition, Pharmaceutical industry, Oncocyte, MD

This announcement marks the successful completion of technology transfer and Oncocytes readiness to deploy TheraSure following the Companys acquisition of Chronix Biomedical.

Key Points: 
  • This announcement marks the successful completion of technology transfer and Oncocytes readiness to deploy TheraSure following the Companys acquisition of Chronix Biomedical.
  • The TheraSure Transplant Monitor, a donor-derived cell-free DNA (dd-cfDNA) test which has shown to successfully achieve an early indication of rejection episodes in organ transplant patients using a digital polymerase chain reaction (dPCR) technique, may allow for timely post-transplant treatment modification to prevent organ damage.
  • Oncocytes patented test has been validated in clinical cohorts that have been published in kidney, liver and heart transplantation.
  • The anticipated speed and accuracy of dPCR testing, particularly the proprietary TheraSure Transplant Monitor test, are important attributes of our technology.

Oncocyte Presents Confirmatory Data for DetermaIO™ at the American Association for Cancer Research Annual Meeting 2022

Retrieved on: 
Monday, April 11, 2022
TMB, Lung, Diagnosis, Forward-looking statement, TME, TIME, Immunotherapy, Kidney, Association, Triple-negative breast cancer, Tumor microenvironment, AACR, SEC, Certification, American Association, Neoplasm, Cancer, Failure, Poster, American Association for Cancer Research, Technology, Goal, OCX, Nasdaq, COVID-19, Intellectual property, U.S. Securities and Exchange Commission, GLOBE, ICIS, Physician, West Pharmaceutical Services explosion, Bladder cancer, Maintenance, Accounting, Patient, ICI, MUC, Medical imaging, Oncocyte

IRVINE, Calif., April 11, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey, today will present data at the American Association for Cancer Research (AACR) Annual Meeting 2022.

Key Points: 
  • IRVINE, Calif., April 11, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey, today will present data at the American Association for Cancer Research (AACR) Annual Meeting 2022.
  • The data is from a real-world cohort of patients with bladder cancer or metastatic urothelial cancer (mUC) and confirms the association of results from the Companys DetermaIO test with response to treatment with immune checkpoint inhibitors (ICI).
  • In this confirmatory study, patients were treated with all four agents and DetermaIO identified responders, regardless of which agent the patients received.
  • DetermaRx identifies early-stage lung cancer patients who are at high risk for cancer recurrence and who may benefit from adjuvant chemotherapy.

Oncocyte to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Retrieved on: 
Thursday, February 10, 2022
Tumor microenvironment, GLOBE, Pharmaceutical Services Negotiating Committee, Conference, Company, Cancer, Digital health, Oncocyte, Patient, Diagnosis, OCX, Neoplasm, Physician, Nasdaq, Medical imaging

IRVINE, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey, today announced that management will present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference.

Key Points: 
  • IRVINE, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey, today announced that management will present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference.
  • Investors interested in meeting with the Oncocyte management team during these events should contact their respective BTIG representatives.
  • This presentation will not be webcast due to the format of the conference.
  • DetermaIO, a gene expression test currently used as a research-use only tool, assesses the tumor microenvironment to predict response to immunotherapies.

Oncocyte Announces Development and Co-Marketing Agreement with Thermo Fisher Scientific to Expand Access to Precision Oncology

Retrieved on: 
Tuesday, January 18, 2022
Research, Forward-looking statement, Patient, Technology, JAMA Network Open, Accounting, Conference, IVD, SEC, Thermo Fisher Scientific, Precision medicine, NGS, COVID-19, West Pharmaceutical Services explosion, GeneXus, Lists of television programs, U.S. Securities and Exchange Commission, Intellectual property, GLOBE, Health, Decision-making, Nasdaq, Goal, Company, Diagnosis, Tumor microenvironment, Immunohistochemistry, Oncocyte, IHC, Certification, Cancer, Neoplasm, List of American Medical Association journals, Immunotherapy, OCX, Maintenance, Failure, Physician, Medical device, Medical imaging

IRVINE, Calif., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing clear insights that inform critical decisions in the diagnosis, treatment, and monitoring of cancer, today announced a development and co-marketing agreement for two distributed in vitro diagnostic (IVD) assays on Thermo Fisher Scientific’s Ion Torrent™ Genexus™ System.* The agreement also grants Oncocyte rights to develop future companion diagnostics on the Genexus System.

Key Points: 
  • * The agreement also grants Oncocyte rights to develop future companion diagnostics on the Genexus System.
  • DetermaIO may predict response to immuno-oncology therapies based on data demonstrating potential pan-cancer utility and improvement over current standard-of-care tests.
  • We have developed our Determa menu to ultimately become regulated kits for distribution ex-US on an IVD instrument.
  • By partnering with Oncocyte to validate and co-develop new IVD assays, we are working to expand access to genomic profiling and spread the benefits of precision medicine to more patients.

Oncocyte Announces Peer-Reviewed Publication in Cancers Showing Utility of DetermaCNI™ Blood-Only Monitoring Test to Detect Recurrence Following Surgery in Epithelial Ovarian Cancer

Retrieved on: 
Tuesday, January 4, 2022
CNI, Gene, DNA, Diagnosis, Disease, Recurrence, Biomarker, Immunotherapy, Clinical Cancer Research, Neoplasm, HIV disease progression rates, Cancer, Method, Gynecologic cancer disparities in the United States, Goal, Doctor of Philosophy, Circulating tumor DNA, OCX, GLOBE, Ovarian cancer, Company, Nucleic acid thermodynamics, Physician, CEO, CMS, MD, Pharmaceutical Services Negotiating Committee, CTO, Medicare, Publication, Patient, Death, Nasdaq, Tumor microenvironment, Genome, NGS, Medical imaging, Pharmaceutical industry, Oncocyte

IRVINE, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing clear insights that inform critical decisions in the diagnosis, treatment, and monitoring of cancer, today announced the publication of data showcasing the clinical utility of its DetermaCNI™ blood-based monitoring test in the peer-reviewed journal Cancers.

Key Points: 
  • One of the goals of the study was to evaluate the role of the CNI score in monitoring patients response to treatment, commonly platinum-based adjuvant chemotherapy following surgery.
  • These study results suggest the test has the potential to impact treatment change at crucial points for patients with ovarian cancer.
  • DetermaRx identifies early-stage lung cancer patients who are at high risk for cancer recurrence and who may benefit from adjuvant chemotherapy.
  • The Companys pipeline of tests in development also includes DetermaTx, which will assess mutational status of a tumor, blood-based monitoring test DetermaCNI, and long-term recurrence monitoring test DetermaMx.

Oncocyte to Present New Data on DetermaIO Clinical Test for Immunotherapy Response in Triple Negative Breast Cancer at San Antonio Breast Cancer Symposium 2021

Retrieved on: 
Thursday, December 2, 2021
Patient, 2021 Essex County Council election, Lung, Company, Diagnosis, Cancer, Tumor microenvironment, Pharmaceutical Services Negotiating Committee, Oncocyte, Biomarker, Physician, Nasdaq, Neoplasm, GLOBE, TME, OCX, Immunotherapy, Medical imaging

IRVINE, Calif., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing clear insights that inform critical decisions in the diagnosis, treatment, and monitoring of cancer, today announced that it will present new data from ongoing clinical research evaluating the 27-gene DetermaIO™ test at the 2021 San Antonio Breast Cancer Symposium (SABCS 2021), taking place December 7-10, 2021.

Key Points: 
  • Recently launched for clinical use, DetermaIO has shown to predict response to immunotherapy in lung, bladder, renal, and triple negative breast cancer, suggesting a pan-cancer utility in both primary and metastatic settings.
  • Following are details of the data accepted to SABCS 2021:
    The abstracts are currently available online at the SABCS 2021 website.
  • The Companys DetermaIO test is a precision diagnostic designed to determine the likelihood of response to immunotherapy, and is the first and only test to measure the entire tumor microenvironment (TME).
  • DetermaIO, a gene expression test currently used as a research-use only tool, assesses the tumor microenvironment to predict response to immunotherapies.

Progenity Appoints Adi Mohanty as Chief Executive Officer

Retrieved on: 
Tuesday, November 9, 2021
Baxter International, Lineage Cell Therapeutics, Private Securities Litigation Reform Act, Financial condition report, Clarkson University, Genomics, SAN, Epigenomics, CEO, Disease, MBA, Regenerative medicine, Growth, Investment, Shire (pharmaceutical company), COVID-19, Proteomics, Black–Scholes model, Safe harbor, Biotechnology, Metabolomics, GLOBE, Saint, Oncocyte, GAAP, SEC, The O.C., Analysis, Result, Chemical engineering, Nasdaq, Employment, Management, Pharmaceutical industry

SAN DIEGO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced the appointment of Adi Mohanty as Chief Executive Officer of the company, effective November 8, 2021.

Key Points: 
  • SAN DIEGO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced the appointment of Adi Mohanty as Chief Executive Officer of the company, effective November 8, 2021.
  • To this end, we are delighted to welcome Adi Mohanty to Progenity as Chief Executive Officer.
  • Adi Mohanty is an experienced biotech business leader with a track record of several successful product development and approvals followed by rapid commercialization.
  • Progenity also announced the grant of an inducement award to Adi Mohanty pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.

Modern Healthcare Recognizes Oncocyte as One of the 2021 Best Places to Work in Healthcare

Retrieved on: 
Thursday, September 16, 2021
Aurora, Workforce, The Last Best Place, OCX, Modern Healthcare, Oncocyte, Patient, Nasdaq, Empathy, Time, Industry, GLOBE, Organization, Diagnosis, Cancer, Medicine, Pharmaceutical industry

Modern Healthcare will publish a special supplement featuring a ranked list of all the winners along with the September 20 issue of Modern Healthcare.

Key Points: 
  • Modern Healthcare will publish a special supplement featuring a ranked list of all the winners along with the September 20 issue of Modern Healthcare.
  • We congratulate the Best Places to Work in Healthcare for eliciting loyalty from their workforce and communities during harrowing times."
  • Oncocytes final ranking on the Best Places list will be celebrated at the 2021 Best Places to Work in Healthcare awards gala on September 16 at the Radisson Blu Aqua Hotel Chicago.
  • For more information or questions on the 2021 Best Places to Work in Healthcare recognition program or awards gala, please contact:

Oncocyte to Participate in the 5th Annual Lake Street Capital Markets Best Ideas Growth Conference

Retrieved on: 
Tuesday, September 7, 2021

IRVINE, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics and monitoring company with the mission to improve patient outcomes by providing clear insights that inform critical decisions in the diagnosis, treatment, and monitoring of cancer, today announced that management will participate in one-on-one and group investor meetings at the 5th Annual Lake Street Capital Markets Best Ideas Growth Conference.

Key Points: 
  • IRVINE, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics and monitoring company with the mission to improve patient outcomes by providing clear insights that inform critical decisions in the diagnosis, treatment, and monitoring of cancer, today announced that management will participate in one-on-one and group investor meetings at the 5th Annual Lake Street Capital Markets Best Ideas Growth Conference.
  • Investors interested in meeting with the Oncocyte management team during these events should contact their respective Lake Street Capital Markets representatives.
  • Oncocyte is a precision diagnostics and monitoring company with the mission to improve patient outcomes by providing clear insights that inform critical decisions in the diagnosis, treatment, and monitoring of cancer.
  • The Companys tests are designed to help provide clarity and confidence to physicians and their patients at every stage.

Oncocyte Launches First Real-World Evidence (RWE) Registry to Evaluate Biomarker Impact on Early-Stage Lung Cancer Treatment Decisions and Outcomes

Retrieved on: 
Tuesday, August 17, 2021
RW, Company, Standard of care, University, Observation, Adjuvant, Journal of Thoracic Oncology, Cancer, Prognosis, EGFR, Large-cell lung carcinoma, Biomarker, West Pharmaceutical Services explosion, Surgeon, Diagnosis, GLOBE, Medical Affairs Bureau, Decision-making, Physician, Science, Research, Woodward, Lung cancer, IIA, Tumor microenvironment, OCX, Â, Biology, Risk, Patient, NCCN, Hospital, Oncocyte, VP, Recurrence, Neoplasm, Hospital of the University of Pennsylvania, Pharmaceutical industry, Medical imaging

IRVINE, Calif., Aug. 17, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to provide clear insights that inform critical decisions in cancer treatment, announced today the launch of a nationwide, prospective, real-world (RW) registry for patients with potentially curable early-stage lung cancer. The study is entitled the Predictive Assay for Decision Making in Adjuvant Therapy (PADMA) Registry.

Key Points: 
  • This registry was created to collect data that may demonstrate the impact of biomarker-guided treatment decisions on patients with completely resected stage I and IIA non-squamous non-small cell lung cancer across multiple academic and community cancer centers in the United States.
  • Biomarker tests are playing an increasingly important role in guiding cancer treatment.
  • The PADMA Registry, which utilizes Oncocytes DetermaRxTM test, will be the first RW initiative to evaluate the use of biomarkers in early-stage lung cancer.
  • DetermaRx identifies early-stage lung cancer patients who are at high risk for cancer recurrence and who may benefit from adjuvant chemotherapy.